Bain Capital Life Sciences Investors as of Sept. 30, 2025
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 21 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Heartflow Inc/Sh (HTFL) | 27.8 | $419M | 12M | 33.66 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 20.2 | $305M | 11M | 28.44 | |
| Cidara Therapeutics Com New (CDTX) | 19.2 | $289M | 3.0M | 95.76 | |
| Pharvaris N V (PHVS) | 5.3 | $79M | 3.2M | 24.95 | |
| Olema Pharmaceuticals (OLMA) | 4.4 | $67M | 6.8M | 9.79 | |
| Savara (SVRA) | 4.2 | $63M | 18M | 3.57 | |
| Dianthus Therapeutics (DNTH) | 3.4 | $52M | 1.3M | 39.35 | |
| Solid Biosciences Com New (SLDB) | 3.2 | $49M | 7.9M | 6.17 | |
| Upstream Bio (UPB) | 3.0 | $46M | 2.4M | 18.81 | |
| Rapid Micro Biosystems Class A Com (RPID) | 1.9 | $28M | 8.4M | 3.34 | |
| Tango Therapeutics (TNGX) | 1.5 | $23M | 2.7M | 8.40 | |
| Cabaletta Bio (CABA) | 1.5 | $23M | 9.7M | 2.34 | |
| Kyverna Therapeutics (KYTX) | 1.3 | $20M | 3.4M | 6.00 | |
| Annexon (ANNX) | 1.1 | $16M | 5.2M | 3.05 | |
| X4 Pharmaceuticals Com New (XFOR) | 0.6 | $8.3M | 2.4M | 3.42 | |
| Atea Pharmaceuticals (AVIR) | 0.5 | $7.2M | 2.5M | 2.90 | |
| Xilio Therapeutics (XLO) | 0.3 | $3.8M | 4.6M | 0.84 | |
| Mersana Therapeutics (MRSN) | 0.2 | $2.7M | 347k | 7.76 | |
| C4 Therapeutics Com Stk (CCCC) | 0.2 | $2.5M | 1.1M | 2.22 | |
| Century Therapeutics (IPSC) | 0.1 | $1.8M | 3.5M | 0.50 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $1.7M | 100k | 17.11 |
